Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.14 per share a year ago.

Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to...

The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend i...

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.

HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses ...

Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of I...

Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company tre...

Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023. Another INDUKINE molecule being developed in the...

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.53 per share a year ago.

ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.56 per share a year ago.

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for t...

Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.33% and 18.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t...

JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.

Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ: HOWL) WTX-613. WTX-613 is a differentiated, condi...